Gözden Kaçan Tehdit: Heterodirenç Tanısal Zorluklar ve Moleküler Mekanizmalar
Özet
Heterodirenç, fenotipik olarak duyarlı görünen bakteri popülasyonları içinde düşük sıklıkta bulunan ancak yüksek antibiyotik konsantrasyonlarına dirençli alt grupların varlığı ile karakterize edilen, giderek artan klinik öneme sahip bir antimikrobiyal direnç fenomenidir. Güncel çalışmalar, gram negatif patojenler arasında %18-31 oranında, bazı antibiyotik-bakteri kombinasyonlarında ise %27,4'e varan heterodirençli izolat sıklığı raporlamaktadır. Bu alt popülasyonlar rutin antimikrobiyal duyarlılık testleri ile tespit edilemediğinden, klinik olarak "duyarlı" kabul edilen izolatlarda beklenmedik tedavi başarısızlıkları, uzamış enfeksiyonlar ve direnç gelişimi gözlenebilmektedir. Heterodirencin ana mekanizmaları arasında tandem gen amplifikasyonu, plazmid kopya sayısı artışı, efluks pompa aktivasyonu ve hücre zarı değişiklikleri yer almaktadır. Tanısal açıdan, altın standart olarak kabul edilen popülasyon analiz profili (PAP) yöntemi mevcut olmakla birlikte, standardizasyon eksikliği ve uygulama zorluğu nedeniyle rutin kullanımı sınırlıdır. EUCAST ve CLSI rehberlerinde heterodirencin tanısına yönelik standart protokol bulunmaması, bu alandaki en büyük zorluklardan birini oluşturmaktadır. Bu derleme, heterodirencin moleküler mekanizmalarını, tanı yöntemlerini, klinik etkilerini ve gelecek perspektiflerini kapsamlı olarak ele almakta; hızlı tanı teknolojilerinin geliştirilmesi, klinik farkındalığın artırılması ve standardize protokollerin oluşturulması gereksinimini vurgulamaktadır.
Referanslar
Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019;17(8):479–96. https://doi.org/10.1038/s41579-019-0218-1
Alexander HE, Leidy G. Mode of action of streptomycin on type b Haemophilus influenzae. II. Nature of resistant variants. J Exp Med. 1947;85(6):607–21.
Sutherland R, Rolinson GN. Characteristics of methicillin-resistant staphylococci. J Bacteriol. 1964;87(4):887–99.
Kayser FH, Benner EJ, Hoeprich PD. Acquired and native resistance of Staphylococcus aureus to cephalexin and other beta-lactam antibiotics. Appl Microbiol. 1970;20(1):1–5.
El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev. 2015;28(1):191–207. https://doi.org/10.1128/CMR.00058-14
Matteo MJ, Granados G, Olmos M, Wonaga A, Catalano M. Helicobacter pylori amoxicillin heteroresistance due to point mutations in PBP-1A in isogenic isolates. J Antimicrob Chemother. 2008;61(2):474–7.
Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, et al. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J. 2009;33(2):368–74.
Folkvardsen DB, Thomsen VO, Rigouts L, Rasmussen EM, Bang D, Bernaerts G, et al. Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods. J Clin Microbiol. 2013;51(12):4220–2.
Casapao AM, et al. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(8):4636–41.
Kang CK, et al. agr functionality affects clinical outcomes in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis. 2017;36(12):2187–91.
Wang Z, Chen Q, Zhang J, Yan H, Chen Y, Chen C, et al. High prevalence of unstable antibiotic heteroresistance in cyanobacteria causes resistance underestimation. Water Res. 2021;202:117430. https://doi.org/10.1016/j.watres.2021.117430
Dewachter L, Fauvart M, Michiels J. Bacterial heterogeneity and antibiotic survival: Understanding and combatting persistence and heteroresistance. Mol Cell. 2019;76(2):255–67. https://doi.org/10.1016/j.molcel.2019.09.028
Howden BP, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heteroresistant strains. Clin Microbiol Rev. 2010;23(1):99–139. https://doi.org/10.1128/CMR.00042-09
Band VI, Weiss DS. Heteroresistance: A cause of unexplained antibiotic treatment failure? PLoS Pathog. 2019;15(6):e1007726. https://doi.org/10.1371/journal.ppat.1007726
Waters VJ, Kidd TJ, Canton R, et al. Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections. Clin Infect Dis. 2019;69(11):1812–6. https://doi.org/10.1093/cid/ciz364
Reams AB, Kofoid E, Savageau M, Roth JR. Duplication frequency in a population of Salmonella enterica rapidly approaches steady state with or without recombination. Genetics. 2010;184(4):1077–94.
Nicoloff H, Hjort K, Levin BR, et al. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification. Nat Microbiol. 2019;4(3):504–14. https://doi.org/10.1038/s41564-018-0342-0
Dersch, P., Khan, M. A., Mühlen, S., & Görke, B. (2017). Roles of Regulatory RNAs for Antibiotic Resistance in Bacteria and Their Potential Value as Novel Drug Targets. Frontiers in microbiology, 8, 803. https://doi.org/10.3389/fmicb.2017.00803
Zhao, Z., Yang, T., Xiang, G., Zhang, S., Cai, Y., Zhong, G., Pu, J., Shen, C., Zeng, J., Chen, C., & Huang, B. (2024). A novel small RNA PhaS contributes to polymyxin B-heteroresistance in carbapenem-resistant Klebsiella pneumoniae. Emerging microbes & infections, 13(1), 2366354. https://doi.org/10.1080/22221751.2024.2366354
Yang, J. H., Bhargava, P., McCloskey, D., Mao, N., Palsson, B. O., & Collins, J. J. (2017). Antibiotic-Induced Changes to the Host Metabolic Environment Inhibit Drug Efficacy and Alter Immune Function. Cell host & microbe, 22(6), 757–765.e3. https://doi.org/10.1016/j.chom.2017.10.020
Sorg R, Veening JW. Microscale insights into pneumococcal antibiotic mutant selection windows. Nat Commun. 2015;6:8773. https://doi.org/10.1038/ncomms9773
Turner R, Ratcliffe E, Wheeler R, et al. Peptidoglycan architecture can specify division planes in Staphylococcus aureus. Nat Commun. 2010;1:26. https://doi.org/10.1038/ncomms1025
Gutiérrez R, Ram Y, Berman J, de Sousa KCM, Nachum-Biala Y, Britzi M, et al. Adaptive resistance mutations at suprainhibitory concentrations independent of SOS mutagenesis. Mol Biol Evol. 2021;38(10):4095–4115. https://doi.org/10.1093/molbev/msab196
Chen L, Lin J, Lu H, et al. Deciphering colistin heteroresistance in Acinetobacter baumannii clinical isolates from Wenzhou, China. J Antibiot. 2020;73:463–470. https://doi.org/10.1038/s41429-020-0289-2
Zhang Y, Liu D, Liu Y, Li Q, Liu H, Zhou P, et al. Detection and characterization of eravacycline heteroresistance in clinical bacterial isolates. Front Microbiol. 2024;15:1332458. https://doi.org/10.3389/fmicb.2024.1332458
Chen Y, Hu D, Zhang Q, Liao XP, Liu YH, Sun J. Efflux pump overexpression contributes to tigecycline heteroresistance in Salmonella enterica serovar Typhimurium. Front Cell Infect Microbiol. 2017;7:37. https://doi.org/10.3389/fcimb.2017.00037
Machado D, Antunes J, Simões J, Perdigão J, Couto I, McCusker M, et al. Contribution of efflux to colistin heteroresistance in a multidrug resistant Acinetobacter baumannii clinical isolate. J Med Microbiol. 2018;67:740–749. https://doi.org/10.1099/jmm.0.000741
Karakonstantis S, Saridakis I. Colistin heteroresistance in Acinetobacter spp.: Systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. Int J Antimicrob Agents. 2020;56(2):106065. https://doi.org/10.1016/j.ijantimicag.2020.106065
Jorge P, Magalhães AP, Grainha T, Alves D, Sousa AM, Lopes SP, Pereira MO. Antimicrobial resistance three ways: healthcare crisis, major concepts and the relevance of biofilms. FEMS Microbiol Ecol. 2019;95(8):fiz115. https://doi.org/10.1093/femsec/fiz115
Choi AJ, Bennison DJ, Kulkarni E, Azar H, Sun H, Li H, et al. Aminoglycoside heteroresistance in Enterobacter cloacae is driven by the cell envelope stress response. mBio. 2024;15(4):e01699-24. https://doi.org/10.1128/mbio.01699-24
Lo-Ten-Foe JR, de Smet AMG, Diederen BMW, Kluytmans JAJW, van Keulen PHJ. Comparative evaluation of the VITEK 2, disk diffusion, Etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51(11):3726–30.
Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Hetero-resistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50(9):2946–50.
Stojowska-Swędrzyńska K, Łupkowska A, Kuczyńska-Wiśnik D, Laskowska E. Antibiotic heteroresistance in Klebsiella pneumoniae. Int J Mol Sci. 2022;23(1):449. https://doi.org/10.3390/ijms23010449.
Hira J, Singh B, Halder T, et al. Single-cell phenotypic profiling and backtracing exposes and predicts clinically relevant subpopulations in isogenic Staphylococcus aureus communities. Commun Biol. 2024;7:1228. https://doi.org/10.1038/s42003-024-06894-z
Roch M, Sierra R, Andrey DO. Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside. Clin Microbiol Infect. 2023;29(3):320–5.
Yusof A, Engelhardt A, Karlsson A, Bylund L, Vidh P, Mills K, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol. 2008;46(9):3042–7.
van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, Paterson DL, Gosbell IB. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol. 2011;49(4):1489–94.
Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib R. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and agar screening methods. J Clin Microbiol. 2011;49(6):2147–50.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 33rd ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2023.
EUCAST. European Committee on Antimicrobial Susceptibility Testing: Breakpoint tables for interpretation of MICs and zone diameters. 2024. Available from: https://www.eucast.org/clinical_breakpoints
